Bronchiolitis Obliterans Syndrome Market Report 2026

The bronchiolitis obliterans syndrome market size has grown strongly in recent years. It will grow from $1.59 billion in 2025 to $1.73 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to organ transplantation growth, chronic graft rejection cases, hospital pulmonary care, immunosuppressant usage, limited early diagnostics.

The bronchiolitis obliterans syndrome market size is expected to see strong growth in the next few years. It will grow to $2.43 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to transplant procedure growth, early detection technologies, personalized immunotherapy, specialty respiratory centers, long-term patient management. Major trends in the forecast period include increased monitoring post transplantation, growth of immunosuppressive therapies, expansion of early diagnostic testing, focus on long-term lung function preservation, rising demand for specialized pulmonary care.

The growing number of lung transplantations is expected to drive the growth of the bronchiolitis obliterans syndrome market in the coming years. Lung transplantation is a surgical procedure in which a damaged or malfunctioning lung is replaced with a healthy donor lung to improve respiratory function. The number of lung transplants is increasing due to advancements in surgical techniques, which have improved success rates and reduced complications, making the procedure safer and more widely accessible. Lung transplantation can effectively treat advanced bronchiolitis obliterans syndrome by replacing diseased lungs with healthy ones, thereby enhancing breathing and overall lung function. For instance, in January 2025, according to the Organ Procurement and Transplantation Network, a US-based non-profit scientific and educational organization, lung transplants increased from 3,026 in 2023 to 3,340 in 2024, representing a 10.4% growth. Therefore, the rising number of lung transplantations is driving the bronchiolitis obliterans syndrome market.

The increasing number of clinical trials is expected to further propel the growth of the bronchiolitis obliterans syndrome market. Clinical trials are research studies conducted in humans to evaluate the safety, efficacy, and effectiveness of medical interventions, including drugs, devices, procedures, or behavioral therapies. The growth in clinical trials is driven by the rising demand for personalized medicine, which requires more studies to validate targeted, gene-based therapies. Clinical trials for bronchiolitis obliterans syndrome focus on testing new therapies designed to reduce inflammation, preserve lung function, and improve disease management while enhancing understanding of disease progression and treatment safety. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, the number of industry-initiated clinical trials in the UK increased from 411 in 2022 to 426 in 2023, with a 16.5% rise in Phase III trials. Therefore, the growing number of clinical trials is supporting the expansion of the bronchiolitis obliterans syndrome market.

Major companies in the bronchiolitis obliterans syndrome market are focusing on developing advanced solutions such as at-home nebulized therapy to improve medication adherence and slow disease progression through targeted, continuous treatment. At-home nebulized therapy delivers liquid medication as a breathable mist directly to the lungs via a nebulizer, allowing patients to manage respiratory conditions conveniently at home. For instance, in March 2023, Renovion, Inc., a US-based clinical-stage pharmaceutical company, launched ARINA-1, which received Food and Drug Administration (FDA) Fast Track Designation for its potential to prevent the progression of bronchiolitis obliterans syndrome (BOS) in patients with bilateral lung transplants. This Fast Track status allows for more frequent communication with the FDA and prioritizes ARINA-1 for accelerated development and review, highlighting Renovion’s commitment to advancing respiratory health through innovative, patient-centered therapeutics.

Major companies operating in the bronchiolitis obliterans syndrome market are Novartis AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, AstraZeneca plc, Sanofi S.A., Johnson & Johnson (Janssen), AbbVie Inc., Bristol-Myers Squibb Company, Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals Incorporated, United Therapeutics Corporation, Insmed Incorporated, Viatris Inc., Zydus Lifesciences Ltd., Cadila Pharmaceuticals Ltd.

North America was the largest region in the bronchiolitis obliterans syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bronchiolitis obliterans syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bronchiolitis obliterans syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the bronchiolitis obliterans syndrome market by increasing the cost of importing immunosuppressants, corticosteroids, diagnostic equipment, and oxygen therapy systems. Medication-based treatments and lung transplant procedures are most impacted, particularly in North America and Europe due to reliance on global transplant and pharmaceutical supply chains. Asia-Pacific diagnostic centers are also affected by higher imaging and testing costs. However, tariffs are encouraging localized drug production and regional medical device manufacturing, strengthening long-term treatment availability.

The bronchiolitis obliterans syndrome market research report is one of a series of new reports that provides bronchiolitis obliterans syndrome market statistics, including bronchiolitis obliterans syndrome industry global market size, regional shares, competitors with a bronchiolitis obliterans syndrome market share, detailed bronchiolitis obliterans syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the bronchiolitis obliterans syndrome industry. This bronchiolitis obliterans syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bronchiolitis obliterans syndrome (BOS) is a chronic, progressive lung disorder characterized by inflammation and scarring that narrows the small airways. It often develops as a complication after lung or stem cell transplantation, reflecting chronic graft rejection. Early detection is essential for timely treatment to slow disease progression and preserve lung function.

The main treatment types for bronchiolitis obliterans syndrome include medication, oxygen therapy, and lung transplantation. Medications help manage BOS by controlling inflammation, slowing disease progression, and improving lung function. Diagnosis involves pulmonary function tests, imaging, lung biopsy, and other assessments. Treatments are applied for conditions such as acute bronchiolitis and chronic BOS and are utilized by end-users including hospitals, specialty clinics, diagnostic centers, and others.

The bronchiolitis obliterans syndrome market consists of revenues earned by entities providing services such as psychological counseling, patient monitoring and follow-up care, nutritional support, and pulmonary rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The bronchiolitis obliterans syndrome market also includes sales of high-resolution CT (HRCT) scanner, oxygen concentrators, flexible bronchoscope, and invasive ventilators. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.